NeuroHealing Announces Orphan Drug Designation in Europe for NH001 for the Treatment of Patients Following a Moderate or Severe Traumatic Brain Injury

Provides a 10-Year Regulatory Exclusivity for the European Community Newton, Massachusetts – May 23, 2011. NeuroHealing Pharmaceuticals today announced that the European Commission has granted Orphan Drug Designation EU/3/11/862 for NH001 for the treatment of patients following a moderate or severe traumatic brain injury (TBI). The designation follows a positive opinion from the Committee for…

Details
NeuroHealing

NeuroHealing Announces Strategic Master Services and Investment Agreement with Cato BioVentures

Newton, Massachusetts – May 16, 2011. NeuroHealing Pharmaceuticals today announced that it has entered into a strategic master services and investment agreement with Cato BioVentures. This agreement includes a collaboration with Cato Research Ltd. (“Cato”), its global contract research organization, to assist in the clinical development of NeuroHealing’s lead drug NH001. The investment and collaboration…

Details
NeuroHealing

NeuroHealing Announces Issuance of U.S. Patent for Brain Injury Treatment

Newton, Massachusetts – May 9, 2011. NeuroHealing Pharmaceuticals announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application 11/240,281 entitled “High Potency Dopaminergic Treatment of Neurological Impairment Associated with Brain Injury.” U.S. Patent 7,943,632 will issue May 17, 2011. The patent claims cover methods and…

Details
NeuroHealing

Positive Results of Phase II Clinical Study for the Treatment of Sialorrhea Presented at Parkinson’s Disease Congress

Newton, Massachusetts – December 10, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the presentation of clinical trial results with NH004 for the treatment of sialorrhea (uncontrolled drooling) in Parkinson’s disease patients. The presentation today at the International Congress on Mental…

Details
NeuroHealing

NeuroHealing Awarded Qualified Therapeutic Development Project Grant

Grant Supports Development of NH001 for the Treatment of Patients in a Coma, Vegetative State or Minimally Conscious State Following a Traumatic Brain Injury Newton, Massachusetts – November 3, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, today announced that it has…

Details
NeuroHealing